RHABDOMYOSARCOMA

This study tests a personalized vaccine made from each patient's unique tumor proteins. It is for children and young adults with metastatic Ewing sarcoma, rhabdomyosarcoma, or synovial sarcoma who have completed standard treatment. The goal is to see if the vaccine is safe and ca…

This early-phase trial tests a new type of immunotherapy for adults with solid tumors that have a protein called GPC3 on their surface. Researchers take a patient's own T cells, add genes to help them recognize and attack GPC3-positive cancer cells, and also include a safety swit…

This study tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy can help children whose solid tumors have come back or not responded to treatment. About 23 children with relapsed or refractory solid tumors (including rhabdomyosarcoma) will receive the…

This early-stage trial tests a new treatment for children and young adults with solid tumors that have come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The m…

This study tests a radioactive drug called Lu-177 edotreotide in children aged 2 to 17 with tumors that have a specific marker (SSTR). The goal is to find the right dose and check if it is safe. About 20 children whose tumors came back or did not respond to prior treatment will t…

This study tests a stem cell transplant that removes certain immune cells (alpha/beta T cells and CD19+ B cells) and adds a drug called zoledronic acid to help the donor cells fight solid tumors that have come back or not responded to treatment. It includes children and young adu…

This early-stage trial tests a new treatment using the body's own immune cells (T cells) that are specially trained to attack cancer. It is for children with certain cancers (rhabdomyosarcoma, Ewing sarcoma, neuroblastoma, or Wilms tumor) that have come back or not responded to s…

This study tests a mix of four drugs (vorinostat, vincristine, irinotecan, and temozolomide) in children, teens, and young adults up to age 30 whose solid tumors or brain cancers have returned or not responded to standard treatment. The main goal is to find the safest dose of vor…

This early-phase trial tests a new treatment called CARE T cells for children whose solid tumors (like liver cancer or Wilms tumor) have returned or not responded to standard care. The treatment involves taking a patient's own immune cells, adding special genes to help them recog…

This study is for children, teens, and young adults (up to age 39) with sarcoma that has spread to a few other places in the body. The goal is to see if giving radiation to those spread spots, along with standard treatment, can help them live longer without the cancer getting wor…

This early-phase trial tests a new treatment for children and young adults (ages 3–39) with rhabdomyosarcoma that has returned or not responded to standard therapy. The treatment uses the patient's own immune cells, modified in a lab to better recognize and attack cancer cells. T…

This early-stage study tests a new type of stem cell transplant for children whose blood cancer or solid tumor has returned or is hard to treat. Doctors use a special method to remove certain immune cells from the donor's stem cells, then give a drug called zoledronate after tran…

This study tests a new drug called PEEL-224 combined with two standard chemotherapy drugs (vincristine and temozolomide) in adolescents and young adults whose sarcomas have returned or not responded to prior treatment. The goal is to find the safest dose and see if the combinatio…

This early-stage study is testing whether a new type of immune cell therapy, called HER2-CAR T cells, combined with drugs that boost the immune system (pembrolizumab or nivolumab), is safe for people with advanced sarcoma. About 25 participants will receive chemotherapy before th…

This study tests an experimental pill called silmitasertib combined with standard chemotherapy in children and young adults (under 30) whose solid tumors (like neuroblastoma or sarcoma) have come back or not responded to treatment. The goal is to find a safe dose and see if the c…

This early-stage trial tests a personalized cell therapy for children and young adults (up to age 21) with solid tumors that have come back or not responded to standard treatment. Doctors take the patient's own immune cells, modify them to recognize a protein called B7-H3 on tumo…

This study tests a new drug called Becotatug Vedotin in children aged 2 to 18 with certain cancers (like head and neck, brain, or kidney tumors) that have come back or spread. The drug targets a protein called EGFR found on many cancer cells. The main goal is to see if the drug i…

This study is testing whether a safe green dye, called ICG, can help surgeons see which lymph nodes might contain cancer in children with solid tumors. About 10 children will receive the dye during surgery, and doctors will check if it makes the right lymph nodes glow. The goal i…

This research study aims to discover new genes that may increase the risk of childhood cancer. Researchers will collect blood samples and health information from 1,500 people in families where cancer clusters. The goal is to build a registry and sample bank to help future diagnos…